A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Bromfenac (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors InSite Vision
- 28 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Aug 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 30 Aug 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.